컨슈머 헬스 수탁제조 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 서비스별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Consumer Health Contract Manufacturing Market Summary

The global consumer health contract manufacturing market size was estimated at USD 138.2 billion in 2025 and is projected to reach USD 278.8 billion by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The market growth can be attributed to the shifting trends toward preventive health and wellness-oriented consumption patterns.

Companies are increasingly outsourcing manufacturing to achieve cost-efficiency and avoid high capital investment while improving scalability. In addition, the proliferation of D2C and emerging wellness brands is expanding the client base for contract manufacturers. Furthermore, strategic outsourcing by large pharmaceutical and nutraceutical companies is enhancing operational focus on core competencies.

The market growth is fueled by an increase in the demand for efficient manufacturing processes, compliance with strict regulations, and specialized expertise. The trend among companies to outsource manufacturing activities to avoid the substantial capital commitments associated with establishing and maintaining in-house production infrastructure has led increase in demand for contract manufacturing in the consumer health industry.

Further, the growing necessity for efficient and cost-effective production processes propels the market. As companies seek to improve operational efficiency while minimizing capital expenditure, many organizations have opted for contract manufacturing services for their production needs. Consumer health segments such as dietary supplements, over-the-counter drugs, and personal care products have gained popularity among consumers, resulting in demand for dedicated manufacturing facilities. In addition, advancements in technology that include automation and sustainability also contribute positively to market growth. Besides, stringent compliance regulations encourage consumer health and pharmaceutical brands to collaborate with contract manufacturing firms to meet the evolving standards of the market.

In addition, innovation and technological advancements in formulation development play a significant role in driving the market growth. Advanced technologies, automation, innovative packaging, and sustainable manufacturing practices are some of the latest trends within this industry. Technological advancements and innovations have led manufacturers to develop efficient and sustainable production practices, as well as innovative packaging to accommodate consumers' changing tastes and preferences. Further, the growing adoption of e-commerce and direct-to-consumer marketing channels is expected to drive the need for flexible and efficient production processes. Such factors are expected to drive the market growth in the upcoming years.

Global Consumer Health Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global consumer health contract manufacturing market based on product, service, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Over-the-counter (OTC) Drugs
• Nutritional Supplements
• Personal Care Products
• Medical Devices
• Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• API Manufacturing
• Finished Dose Manufacturing
• Medical Device Manufacturing
• Packaging & Labelling
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Companies
• Nutraceutical Companies
• Cosmeceutical Companies
• Medical Device Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Service
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Consumer Health Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Accelerating Shift Toward Preventive Health and Wellness-Oriented Consumption
    • 3.2.1.2. Cost-Efficiency and Capital Avoidance Driving Outsourcing Preference Among Brand Owners
    • 3.2.1.3. Proliferation of D2C and Emerging Wellness Brands Creating a Broader Client Base
    • 3.2.1.4. Strategic Outsourcing by Large Pharmaceutical and Nutraceutical Companies to Optimize Core Competencies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Intensifying Regulatory Complexity and Compliance Burden Across Multi-Format Manufacturing Operations
    • 3.2.2.2. Escalating Manufacturing Complexity and Capital Intensity Driven by Diversifying Consumer Format Preferences
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Consumer Health Contract Manufacturing Market: Product Estimates & Trend Analysis

• 4.1. Consumer Health Contract Manufacturing Market, By Product: Segment Dashboard
• 4.2. Consumer Health Contract Manufacturing Market, By Product: Movement Analysis
• 4.3. Consumer Health Contract Manufacturing Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 4.4. Over-the-counter (OTC) Drugs
  • 4.4.1. Over-the-counter (OTC) Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Nutritional Supplements
  • 4.5.1. Nutritional Supplements Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Personal Care Products
  • 4.6.1. Personal Care Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Medical Devices
  • 4.7.1. Medical Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Consumer Health Contract Manufacturing Market: Service Estimates & Trend Analysis

• 5.1. Consumer Health Contract Manufacturing Market, By Service: Segment Dashboard
• 5.2. Consumer Health Contract Manufacturing Market, By Service: Movement Analysis
• 5.3. Consumer Health Contract Manufacturing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 5.4. API Manufacturing
  • 5.4.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Finished Dose Manufacturing
  • 5.5.1. Finished Dose Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Medical Device Manufacturing
  • 5.6.1. Medical Device Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Packaging & Labelling
  • 5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Consumer Health Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Consumer Health Contract Manufacturing Market, By End Use: Segment Dashboard
• 6.2. Consumer Health Contract Manufacturing Market, By End Use: Movement Analysis
• 6.3. Consumer Health Contract Manufacturing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 6.4. Pharmaceutical & Biopharmaceutical Companies
  • 6.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Nutraceutical Companies
  • 6.5.1. Nutraceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Cosmeceutical Companies
  • 6.6.1. Cosmeceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Medical Device Companies
  • 6.7.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Consumer Health Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2025 & 2033
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Australia
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.6. Oman
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.7. Qatar
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Key Participant Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Lonza
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Recipharm AB
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Piramal Consumer Products
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Scapa Healthcare
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Catalent, Inc.
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. SCN BestCo
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Aenova Group
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Ventiz Healthcare
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Bionova
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Aurohealth
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Siegrified AG
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Thermo Fisher Scientific Inc
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives
  • 8.3.13. Famar
    • 8.3.13.1. Company Overview
    • 8.3.13.2. Financial Performance
    • 8.3.13.3. Service Benchmarking
    • 8.3.13.4. Strategic Initiatives
  • 8.3.14. Sirio Pharma Co., Ltd.
    • 8.3.14.1. Company Overview
    • 8.3.14.2. Financial Performance
    • 8.3.14.3. Service Benchmarking
    • 8.3.14.4. Strategic Initiatives
  • 8.3.15. Tishcon Corporation
    • 8.3.15.1. Company Overview
    • 8.3.15.2. Financial Performance
    • 8.3.15.3. Service Benchmarking
    • 8.3.15.4. Strategic Initiatives
  • 8.3.16. Vit-Best Nutrition Inc.
    • 8.3.16.1. Company Overview
    • 8.3.16.2. Financial Performance
    • 8.3.16.3. Service Benchmarking
    • 8.3.16.4. Strategic Initiatives